Metastatic colon cancer specific promoter and uses thereof

Details Metastatic colon cancer specific promoter and uses thereof Metastatic colon cancer specific promoter and uses thereof

2008-04-29

2008-04-29

Chen, Shin-Lin (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C536S023100, C536S024100, C435S320100, C435S455000

Reexamination Certificate

active

10624670

ABSTRACT:
Colon cancer specific promoter sequences and adenovirus vehicles are provided. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.

REFERENCES:
patent: 5112767 (1992-05-01), Roy-Burman et al.
patent: 5677178 (1997-10-01), McCormick
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 5801029 (1998-09-01), McCormick
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6432700 (2002-08-01), Henderson et al.
patent: 6436394 (2002-08-01), Henderson et al.
patent: 6495130 (2002-12-01), Henderson et al.
patent: 6551587 (2003-04-01), Hallenbeck et al.
patent: 6585968 (2003-07-01), Little et al.
patent: 6638762 (2003-10-01), Chang et al.
patent: 6692736 (2004-02-01), Yu et al.
patent: 2001/0053768 (2001-12-01), Gregory
patent: 2003/0104624 (2003-06-01), Clarke et al.
patent: 2003/0118570 (2003-06-01), Hallenbeck et al.
patent: 2003/0129175 (2003-07-01), Hallenbeck et al.
patent: 2003/0157688 (2003-08-01), Von Seggern et al.
patent: WO 92/03563 (1992-03-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 96/18418 (1996-06-01), None
patent: WO 98/29555 (1998-07-01), None
patent: WO 98/35554 (1998-08-01), None
patent: WO 99/25860 (1999-05-01), None
patent: WO 99/59604 (1999-11-01), None
patent: WO 02/067861 (2002-09-01), None
patent: WO 02/068627 (2002-09-01), None
Parks et al, Journal of Virology, 71:3293-3298, 1997.
Alemany et al, Nature Biotechnology, 18:723-727, 2000.
Zhang et al, Science, 276:1268-1272, 1997.
Chen et al, BioDrugs, 15:357-367, 2001.
Abe et al., “Characterization of Cis-Acting Elements Regulating Transcription of The Human DF3 Breast Carcinoma-Associated Antigen (MUC1) Gene”, Proc. Natl. Acad. Sci. USA, Jan. 1993; 90:282-286.
Armitage Jo et al., “Emerging Apolications Of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor”, Blood, 1998; 92(12): 4491-508. 92(12).
Babbiss et al., “Cellular Promoters Incorporated Into The Adenovirus Genome; Effects Of Viral Regulatory Elements On Transcription Rates and Cell Specificity Of Albumin And Beta-Globin Promoters”, 1986; 3798-806.
Berkner, K.L., et al., “Biotechniques”, Eaton Publishing, London, UK 1988.
Bristol et al., “In Vitro And In Vivo Activities Of An Oncolytic Adenoviral Vector Desined to Express GM-CSF”, 2003; 7(6):755-64.
Chang, J. et al., “The Epithelial Mucin, MUC1, Is Expressed On Resting T Lymphocutes And Can function As a Negative Regulator of T Cell Activation”, Cell Immunnology, May 2000; 1; 201(2) 83-88.
Chen Y et al., “CV706,a Prostate Cancer-Specific Adenovirus variant, In Combination With Radiotherapy Produces Synergistic Antitumor Efficacy Without Increasing Toxicity”, Cancer Res. 2001; 61(14):5453-60.
Cleutjens et al., “A 6-KB Promoter Fragment Mimics In Transgenic Mice The Prostate-Specific And Androgen-Regulated Expression Of The Endogenous Prostate-Specific Antigen Gene In Humans”, Aug. 1997; 11(9): 1256-65.
Freidman et al. Cellular Promoters Incorporated Into The Adenovirus Genome; Cell Specificity Of Albumin And Immunoglobulin Expression', Molecular and Cellular Biology, 1986; 6(11) 3791-3797.
Freidman, J.M. et al., “Adenoviral Vectors And Liver Specific Gene Control”, Transcriptional Control Mechanisms, 1987; 421-435.
Furukawa, K. , et al., Effect Of Virus-Modified Tumor cell Extracts, Autologous Mononuclear cell Infusions And Interleukin-2 On Oncolytic Activity Of Effector Cells Of Patients With Advanced Ovarian Cancer', Cancer Immunol. 1989; 30:126-132.
Grooteclaes, et al., “The 6-Kilobase C-erb B2 Promoter Contains Positive and Negative Regulatory Elements Functional In Human Mammary Cell Lines”, Cancer Res., Aug. 1994; 54:4193-4199.
Hallenbeck, P.L., et al., “A Novel Tumor-Specific Replication-Restricted Adenoviral Vector For Gene Therapy Of Hepatocellular Carcinoma”, Human Gene Therapy, 1999; 10:1721-1733.
Henderson, D.R. et al., “Attenuated Replication Competent Adenovirus For Prostate Cancer: CV706 And CV787 Replication-Competent Viruses For Cancer Therapy”, Monographs In Viroloy, Eds. Driever PH& Rabkin SD (Basel, Karger), 2001; 57-80, vol. 22.
Herman, Trends In Biochemical Sciences, 1989; 14(6): 219-222.
Jackson et al., “Internal Intiation Of Ranslation In Eukaryotes”, The Picornavirus Paradigm And Beyond; 1995; 1(10): 985-1000.
Kenney, S., et al., “Viruses As Oncolytic Agents: A New Age For ‘Therapeutic’ Viruses”, J. National Cancer Institute, Aug. 1994; 86:1185-1186.
Kovarik, et al., “Analysis Of The Tissue-Specific Promoter of The MUC1 Gene”, J. Biol. Chem., May 1993; 268:9917-9926.
Li, Y. et al., “A Hepatocellular Carcinoma-Specific Adenovirus Variant, CV890, Eliminates Distant Human Liver Tumors In Combination With Doxorubicin”, Cancer Research, 2001; 6428-6436, vol. 61, No. 17.
Lin et al., “A Tissue-Specific Promoter That Can Drive A Foreign Gene To Express In The Suprabasal Urothelial Cells Of Transgenic Mice”, Proc National Academy Science USA 1995; 92:679-683.
Mach N. et al., “Cytokine-Secreting tumor Cell Vaccines”, Curr Opinion Immunol. 2000; 12(5): 571-5.
Matter et al., “Role of PRL-3, A Human Muscle-Specific Tyrosine Phosphatase, In Angiotensin-II Signaling”, Biochem Biophys Res Communication 2001; 283(5): 1061-8.
Max-Audit, et al., “Transcriptional Regulation Of The Pyruvate Kinase Erythroid-Specific Promoter Isolated From A Patient With Prostate Cancer”, J. Biol. Chem., Mar. 1993; 268:5431-5437.
Miller, et al., “Progress In Transcriptionaly Targeted and Regulated Vectors For Genetic Therapy”, Human Gene Therapy, May 1, 1997; 8:803-815.
Neagoe, G., et al., “Methods Of Active Immunotherapy And Viral Oncolysis In Some Forms Of Cancer”, Rev. Roum. Med. -Med. Int. 1986; 30:126-132.
Pang, et al., “Prostate Tissue Specificity Of The Prostate-Specific Antigen Promoter Isolated From A Patient With Prostate Cancer”, Human Gene Therapy, Nov. 1995; 6:1414-1426.
Pardoll, “Paracrine Cytokine Adjuvants In Cancer Immunotherapy”, Annu Rev Immunol. 1995; 13:399-415.
Reigman et al., “The Promoter Of The Prostate-Specific Antigen Gene Contains A Functional Androgen Responsive Element”, 1991; 5(12) 1921-1930.
Saha et al., “A Phosphatase Associated With Metastasis of Colorectal Cancer”, 2001; Science. 294 (5545): 1343-6.
Shoham, J., et al., “Augmentation Of Tumor Cell Immunogenicity By Viruses—An Approach to Specific Immunotherapy Of Cancer”, Nat. Immun. , Cell Growth Regul., 1990: 9:165-172.
Sinkovics, J.G., “Viral Oncolysates As Human Tumor Vaccines”, Inter, Rev. Immunol. 1991; 7:259-287.
Taneja, S.S., et al., “In Vitro Target Specific Gene therapy For Prostate Cancer Utilizing A Prostate Specific Antigen Promoter-Driven Adenoviral 1 Vector”, Proc. Am. Assn. Cancer Research, 1994; 35:375, Abstract No. 2236, American Association for Cancer Research, Washington, DC.
Yohn, D.S., et al., “Oncolytic Potentials Of Nonhuman Viruses For Human Cancer. II Effects of Five Viruses on Heterotransplantable Human Tumors”, J. Natl. Cancer, Institute, 1968; 41:523-529.
Yu, DC et al., “Selectively Replication Oncolyti Adenoviruses As Cancer Therapeutics”, Current Opinion In Molecular Therapeutics, 2002; 4(5) 435-443.
Yu, DC et al., “Antitumor Synergy Of CV787, A Prostate Cancer-Specific Adenovirus, and Paclitaxel And Docetaxel”, 2001; 517-525; vol. 22.
Yu, DC et al., “The Addition Of Adenovirus Type 5 Region E3 Enables Calydo

Affiliated with

Also associated with

Rating

Metastatic colon cancer specific promoter and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Metastatic colon cancer specific promoter and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metastatic colon cancer specific promoter and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3946213